It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Despite the importance of radiation therapy as a nonsurgical treatment for non-small cell lung cancer (NSCLC), radiation resistance has always been a concern because of poor patient response and outcomes. Therefore, it is crucial to identify novel targets to increase the effectiveness of radiotherapy and investigate the mechanisms underlying radioresistance. Previously, we demonstrated that Spindlin 1 (SPIN1) was related to tumour initiation and progression. In this study, we found that SPIN1 expression was higher in NSCLC tissues and cell lines than in the corresponding controls. SPIN1 overexpression in NSCLC patients was closely correlated with disease progression and poor prognosis. Functionally, SPIN1 depletion inhibited cell proliferation, decreased the percentage of cells in the G2/M phase and suppressed cell migration and invasion. Moreover, SPIN1 knockdown decreased the clonogenic capacity, impaired double-strand break (DSB) repair and increased NSCLC radiosensitivity. Mechanistically, forkhead box M1 (FOXM1) was identified as a key downstream effector of SPIN1 in NSCLC cells. Furthermore, SPIN1 was found to facilitate MDM2-mediated FOXO3a ubiquitination and degradation, leading to FOXM1 upregulation. Moreover, restoration of FOXM1 expression markedly abolished the inhibitory effects and increased radiosensitivity induced by SPIN1 depletion. These results indicate that the SPIN1-MDM2-FOXO3a/FOXM1 signalling axis is essential for NSCLC progression and radioresistance and could serve as a therapeutic target for increasing radiotherapy efficacy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 the First Affiliated Hospital of Nanchang University, Department of Oncology, Nanchang, PR China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073); Jiangxi Key Laboratory for Individualized Cancer Therapy, Nanchang, PR China (GRID:grid.412604.5); the First Affiliated Hospital of Nanchang University, Department of Respiratory, Nanchang, PR China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073)
2 the First Affiliated Hospital of Nanchang University, Department of Oncology, Nanchang, PR China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073); Jiangxi Key Laboratory for Individualized Cancer Therapy, Nanchang, PR China (GRID:grid.412604.5)
3 the First Affiliated Hospital of Nanchang University, Department of Respiratory, Nanchang, PR China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073)
4 the First Affiliated Hospital of Nanchang University, Department of Oncology, Nanchang, PR China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073)
5 Jiangxi Key Laboratory for Individualized Cancer Therapy, Nanchang, PR China (GRID:grid.412604.5)